Insulet to Host Three Educational Events at the AADE Conference in
BILLERICA, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced several educational
programs to help health care providers better connect with and treat
their patients living with diabetes. Insulet will exhibit at the 2017
American Association of Diabetes Educators (AADE) Conference in
Indianapolis, Indiana from August 3rd to August 5th.
The Company will exhibit at booth #1311 and will also conduct Omnipod
product demonstrations and a "Pod Challenge", which will include a
donation to AADE for each booth visitor who wears a demo Pod. Insulet
will also host three interactive educational programs:
This Smart News Release features multimedia. View the full release here:
Sex, Insulin and Rock-n-Roll - August 3rd. An
interactive panel will discuss important diabetes-related questions
about sex, alcohol, and body image. Panel members will include:
Moderator Jim Turner: comedian, actor and former host of dLife TV.
Panel Members: Christel Marchand Aprigliano, Chief Executive
Officer, The Diabetes Collective and Diabetes Patient Advocacy
Coalition; Jill Meier, Diabetes Educator; and Dr. William H.
Polonsky, CDE, and Chief Executive Officer, Behavioral Diabetes
Institute, Associate Clinical Professor in Psychiatry.
How to Benefit from Great Food and Healthy Living - August 4th.
Sam Talbot, from the television show, Top Chef, who is also an Omnipod
user, will share favorite recipes and impactful nutrition secrets and
Omnipod - Innovation at Work - August 5th. Will
include insight's into Insulet's innovation and clinical plans for its
future hybrid closed-loop system. Presenters will include Dr. Trang
Ly, Insulet's Vice President and Medical Director, and Davida F.
Kruger, Certified Nurse Practitioner.
To further drive Insulet's growing product pipeline, the Company
recently opened its "Innovation Center of Excellence" located in San
Diego, California, a global hub for technology innovation. This facility
has attracted local talent with vast expertise in Internet of Things,
cloud-based technologies, mobile devices and cyber security. This
growing team is driving Insulet's mission to improve the lives of people
living with diabetes through patient-centric innovation.
"Insulet is developing technologies and solutions that promote
successful diabetes management for people with diabetes, as well as
their health care providers," said Dr. Aiman Malek, Senior Vice
President of Advanced Technology and Engineering. "Our focus on
integrating a user's smartphone into our next-generation technology is
just one example of how we are developing technology to simplify
diabetes management and demonstrates our dedication to provide a truly
innovative and differentiated product platform."
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes easier.
Through its Omnipod Insulin Management System, Insulet seeks to expand
the use of insulin pump therapy among people with insulin-dependent
diabetes. The Omnipod is a revolutionary and easy-to-use tubeless
insulin pump that provides up to three days of non-stop insulin
delivery, without the need to see or handle a needle. Insulet's Delivery
Systems business also partners with global pharmaceutical and
biotechnology companies to adapt the Omnipod technology platform for the
delivery of subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, Insulet Corporation is based in Billerica,
Massachusetts. For more information, please visit: http://www.myomnipod.com.
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 28, 2017 in the section entitled
"Risk Factors," and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170802006488/en/
Investor Relations and Media Contact:
R. Gordon, 978-600-7717
Vice President, Investor Relations and
Source: Insulet Corporation
News Provided by Acquire Media